CD8A and melanoma: For example, imiquimod, a TLR7 agonist, triggers CCL2 secretion from B16-F10-resident mast cells to mobilize anti-tumor CD8α+ plasmacytoid DCs to clear B16-F10-melanomas in a IFNAR1-dependent manner [175].